Miscellaneous treatments for neuroleptic-induced tardive dyskinesia

Soares‐Weiser, Karla; Irving, Claire B; Rathbone, John

doi:10.1002/14651858.cd000208

Cited by 31 publications

(14 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, other studies indicate that lithium only improves a subpopulation of patients (Gerlach et al, 1975; Jus et al, 1978), or fails to show a therapeutic effect in older TD patients (Simpson et al, 1976). Although a previous Cochrane review did not recommend lithium for everyday use in TD (Soares-Weiser & Joy, 2003), a recent nine-year follow-up study suggests a beneficial effect of lithium on TD in some patients using long-term antipsychotics (van Harten et al, 2008). …”

Section: Lithium In Models Of Cns Disorders and Its Clinical Implimentioning

confidence: 99%

Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders

Chiu

Chuang

2010

Pharmacology & Therapeutics

199

198

View full text Add to dashboard Cite

Lithium has been used clinically to treat bipolar disorder for over half a century, and remains a fundamental pharmacological therapy for patients with this illness. Although lithium’s therapeutic mechanisms are not fully understood, substantial in vitro and in vivo evidence suggests that it has neuroprotective/neurotrophic properties against various insults, and considerable clinical potential for the treatment of several neurodegenerative conditions. Evidence from pharmacological and gene manipulation studies support the notion that glycogen synthase kinase-3 inhibition and induction of brain-derived neurotrophic factor-mediated signaling are lithium’s main mechanisms of action, leading to enhanced cell survival pathways and alteration of a wide variety of downstream effectors. By inhibiting N-methyl-D-aspartate receptor-mediated calcium influx, lithium also contributes to calcium homeostasis and suppresses calcium-dependent activation of pro-apoptotic signaling pathways. In addition, lithium decreases inositol 1,4,5-trisphosphate by inhibiting phosphoinositol phosphatases, a process recently identified as a novel mechanism for inducing autophagy. Through these mechanisms, therapeutic doses of lithium have been demonstrated to defend neuronal cells against diverse forms of death insults and to improve behavioral as well as cognitive deficits in various animal models of neurodegenerative diseases, including stroke, amyotrophic lateral sclerosis, fragile X syndrome, as well as Huntington’s, Alzheimer’s, and Parkinson’s diseases, among others. Several clinical trials are also underway to assess the therapeutic effects of lithium for treating these disorders. This article reviews the most recent findings regarding the potential targets involved in lithium’s neuroprotective effects, and the implication of these findings for the treatment of a variety of diseases.

show abstract

Section: Lithium In Models Of Cns Disorders and Its Clinical Implimentioning

confidence: 99%

Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders

Chiu

Chuang

2010

Pharmacology & Therapeutics

199

198

View full text Add to dashboard Cite

show abstract

“…We have conducted and have periodically updated a series of systematic reviews evaluating all possible treatment options for TD. [28][29][30][31][32][33][34][35][36][37][38][39] These reviews were performed under the auspices of the Cochrane Schizophrenia Group, and we followed the Cochrane Collaboration guidelines. 38 To perform those reviews the following methodology was applied: The data from several electronic databases (Biological Abstracts, Cochrane Controlled Trials Register, EMBASE, LILACS, Medline, and PsycLIT) were systematically searched from January 1966 to December 2005 (details of the search strategies are available from the authors).…”

Section: Evidence-based Treatment For Tardive Dyskinesiamentioning

confidence: 99%

Tardive Dyskinesia

Soares‐Weiser¹,

Fernández

2007

Semin Neurol

Self Cite

View full text Add to dashboard Cite

This article provides up-to-date information regarding clinical manifestations, pathophysiology, and evidence-based treatment for tardive dyskinesia (TD). We conducted a comprehensive literature search, including sources such as the Cochrane Library, EMBASE, and Medline; and we manually searched bibliographic references. We also contacted the authors of each included trial. All randomized clinical trials that compared different types of active interventions with placebo or no intervention in patients with neuroleptic-induced TD were included in our data. Two reviewers independently applied the selection criteria to all identified references, appraised the methodological quality of each trial, and extracted the relevant data. Relative risks and 95% confidence intervals were estimated using the fixed effect model. More than 500 randomized trials evaluating over 90 different interventions to treat TD were identified. From those, 45 trials were included in the current reviews. None of the trials pooled on these reviews found a definitive therapy for TD. Clinicians faced with conditions such as TD should carefully weigh the risks and benefits involved with any given intervention.

show abstract

“…42 Reserpine and tetrabenazine are also used. 43 Vitamin E has been studied more extensively but appears to be no better than placebo in improving TD. It may reduce neurologic deterioration if neuroleptic treatment is continued.…”

Section: Treatment Of Dimds In Children Prescribed Neuroleptics and Amentioning

confidence: 99%

Drug‐induced Movement Disorders in Children

Gilbert

2008

Annals of the New York Academy of Sciences

View full text Add to dashboard Cite

This article reviews the current state of knowledge of drug-induced movement disorders (DIMDs) in children. The objective is to aid clinicians who treat children with medications that may induce DIMDs, as well as specialists consulted on DIMDs. As with adults, the most common agents are dopaminergic and dopamine-blocking medications, and prescriptions for these agents have increased markedly in children. Unfortunately, most evidence-based reviews, including those from the Cochrane Collaboration cited here, have few systematic data to analyze. Many publications are small case series. This report attempts to provide useful information, with appropriate caution and discussion of the limitations of what we know.

show abstract

Miscellaneous treatments for neuroleptic-induced tardive dyskinesia

Cited by 31 publications

References 64 publications

Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders

Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders

Tardive Dyskinesia

Drug‐induced Movement Disorders in Children

Contact Info

Product

Resources

About